Pegfilgrastim Home Redirection Outcomes: Effectiveness and Timing of Administration in Primary Prophylaxis of Chemotherapy-Induced Neutropenia

The purpose of this study was to examine the impact of Cigna’s site-of-care home-redirection program on pegfilgrastim effectiveness and timing of administration in preventing complications from chemotherapy-induced neutro­penia among Cigna’s commercially managed patients receiving myelosuppres­sive chemotherapy. Commercial medical claims data from Cigna were used for the study. The sample consisted of 13,493 patients receiving chemotherapy be­tween September 1, 2020, and August 31, 2022. Descriptive and chi-square sta­tistics and logistic regression were conducted to estimate the magnitude and di­rection of associations between pegfilgrastim home redirection and outcomes, such as pegfilgrastim effectiveness and timing of administration. Logistic re­gression analyses revealed that the incidence of neutropenia, fever, pneumo­nia, and sepsis was 32% less likely in patients that underwent home redirection vs those who did not. Similarly, the odds of same-day pegfilgrastim administra­tion were 43% lower in patients that underwent home redirection. This retro­spective, real-world claims study presents significant evidence supporting fa­vorable clinical outcomes associated with Cigna’s site-of-care home-redirection program for pegfilgrastim.